Oncodesign Precision Medicine (OPM) and Servier Announce a Strategic Collaboration to Discover New Therapeutic Targets for Pancreatic Cancer Treatment

Identification and validation of new therapeutic targets against pancreatic cancer - Building a common Artificial Intelligence (AI) analytical platform - Generation and sharing of clinical and biological

Related Keywords

Paris ,France General ,France ,French ,Mathilde Bohin Louis Victor Delouvrier ,Philippe Genne ,Coexya Lyon ,Arthur Rouill ,Walids Kamoun ,Oncodesign Dijon ,Acobiom Montpellier ,Jean Philippe Stephan ,Instagram ,Linkedin ,Servier In Vitro Pharmacology Research Unit ,Twitter ,Facebook ,Servier Group ,Artificial Intelligence ,Drug Discovery ,Oncodesign Precision Medicine ,Pancreatic Ductal Adenocarcinoma ,Vitro Pharmacology Research Unit ,Precision Medicine ,Chief Executive Officer ,Bohin Louis Victor Delouvrier ,Oncodesign ,Precision ,Medicine ,Servier ,Nnounce ,Strategic ,Collaboration ,Discover ,Herapeutic ,Targets ,Pancreatic ,Dancer ,Treatment ,